熱門資訊> 正文
Xoma Royalty通过战略版税股份交易修改最初于2006年与武田建立的合作
2025-12-30 20:38
- XOMA Royalty Corporation Depositary Shs Repr 1/1000th 8.375% Cum Conv Perp Red Pfd Rg Shs Series B(XOMAO) 0
- 武田製藥(TAK) 0
- Takeda's royalty and milestone payment obligations to XOMA Royalty related to mezagitamab will be reduced
- XOMA Royalty will receive payments based on low to mid-single-digit royalties and milestones across a basket of nine development-stage assets that are held within Takeda's externalized assets portfolio.
- Takeda regains a majority of XOMA Royalty's royalty interest in mezagitamab (TAK-079)
- XOMA Royalty will be entitled to payments based on a share of milestones and royalties associated with nine development-stage assets held within Takeda's externalized assets portfolio
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
